failed to cooperate with an independent review of the data used for the study by not allowing any such review to take place. the who decided to resume the trial on 3 june, after reviewing the safety concerns which had been raised. speaking at a press briefing, who's director-general, tedros adhanom ghebreyesus stated that the board had reviewed the available mortality data and had found "no reasons to modify the trial". on 4 july, the who discontinued the hydroxychloroquine trial based on evidence presented at the july who summit on covid-19 research and innovation. the who stated that "these interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized covid-19 patients when compared to standard of care."